,SETDB1NK,

Yu-Hsuan Chang1, Keita Yamamoto2, Takeshi Fujino2

  • 1Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 108-8639, Japan; Division of Molecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-8654, Japan.

Cell reports
|August 3, 2024
PubMed
概括

向SETDB1通过增强自然杀手 (NK) 细胞活性来抑制单细胞急性髓性白血病 (AML) 的生长. 这种方法对治疗AML充满希望,特别是在标准疗法失败时.